Diabetes Health in the News Podcast: Jardiance Reduces Cardiovascular Risk for Type 2 Diabetes
Podcast: Play in new window | Download
Click here to listen to the audio recording of Diabetes Health in News Podcast.
Boehringer Ingelheim and Eli Lilly and Company announced their primary results for the EMPA-REG outcome trial. The study showed that Jardiance® (empagliflozin), significantly reduces the risk for cardiovascular death, by 14% for patients living with type 2 diabetes, who are at a higher risk for a cardiovascular event.
The trial also found:
- There was a 38% reduction in cardiovascular death, with no significant difference, in the risk of non-fatal heart attack or non-fatal strokes
- Treatment with Jardiance also resulted in a 32% lower mortality risk and a 35% reduction in hospitalization for heart failure
The results of the trial were presented at the 51st European Association for the Study of Diabetes, Annual Meeting in Stockholm, Sweden, and was also published in the New England Journal of Medicine.